[1] |
KDIGO Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease [J]. Kidney Int Suppl, 2013, 3(1): 1-150.
|
[2] |
Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis [J]. PLoS One, 2016, 11(7): e0158765.
|
[3] |
Mahmoodi BK, Gansevoort RT, Næss IA, et al. Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts [J]. Circulation, 2012, 126(16): 1964-1971.
|
[4] |
Dubin R, Cushman M, Folsom AR, et al. Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis [J]. BMC Nephrol, 2011, 12: 3.
|
[5] |
Friberg L, Rosenqvist M, Lindgren A, et al. High prevalence of atrial fibrillation among patients with ischemic stroke [J]. Stroke, 2014, 45(9): 2599-2605.
|
[6] |
Ng KP, Edwards NC, Lip GY, et al. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation [J]. Am J Kidney Dis, 2013, 62(3): 615-632.
|
[7] |
Bansal N, Xie D, Sha D, et al. Cardiovascular events after new-onset atrial fibrillation in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study [J]. J Am Soc Nephrol, 2018, 29(12): 2859-2869.
|
[8] |
Massicotte-Azarniouch D, Kuwornu JP, Carrero JJ, et al. Incident atrial fibrillation and the risk of congestive heart failure, myocardial infarction, end-stage kidney disease, and mortality among patients with a decreased estimated GFR [J]. Am J Kidney Dis, 2018, 71(2): 191-199.
|
[9] |
Manzoor BS, Cheng WH, Lee JC, et al. Quality of pharmacist-managed anticoagulation therapy in long-term ambulatory settings: a systematic review [J]. Ann Pharmacother, 2017, 51(12): 1122-1137.
|
[10] |
Kleinow ME, Garwood CL, Clemente JL, et al. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic [J]. J Manag Care Pharm, 2011, 17(7): 523-530.
|
[11] |
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials [J]. Lancet, 2014, 383(9921): 955-962.
|
[12] |
Katz DF, Maddox TM, Turakhia M, et al. Contemporary trends in oral anticoagulant prescription in atrial fibrillation patients at low to moderate risk of stroke after guideline-recommended change in use of the CHADS2 to the CHA2DS2-VASc score for thromboembolic risk assessment: analysis from the National Cardiovascular Data Registry′s outpatient practice innovation and clinical excellence atrial fibrillation registry [J]. Circ Cardiovasc Qual Outcomes, 2017, 10(5): e003476.
|
[13] |
Vinogradova Y, Coupland C, Hill T, et al. Risks and benefits of direct oral anticoagulants versus warfarin in a real-world setting: cohort study in primary care [J]. BMJ, 2018, 362: k2505.
|
[14] |
Yeh CH, Fredenburgh JC, Weitz JI. Oral direct factor Xa inhibitors [J]. Circ Res, 2012, 111(8): 1069-1078.
|
[15] |
Kumar S, Lim E, Covic A, et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week [J]. J Am Coll Cardiol, 2019, 74(17): 2204-2215.
|
[16] |
Steffel J, Collins R, Antz M, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation [J]. Europace, 2021, 23(10): 1612-1676.
|
[17] |
张弛,沈珑,刘晓琰,等. 新型口服抗凝药贝曲沙班[J]. 中国新药杂志,2019, 28(2): 142-145.
|
[18] |
Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis [J]. N Engl J Med, 2017, 377(5): 431-441.
|
[19] |
Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors [J]. N Engl J Med, 2016, 375(12): 1131-1141.
|
[20] |
Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: guidance from the anticoagulation forum [J]. Am J Hematol, 2019, 94(6): 697-709.
|
[21] |
Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (randomized evaluation of long-term anticoagulation therapy) trial analysis [J]. Circulation, 2014, 129(9): 961-970.
|
[22] |
Yao X, Inselman JW, Ross JS, et al. Comparative effectiveness and safety of oral anticoagulants across kidney function in patients with atrial fibrillation [J]. Circ Cardiovasc Qual Outcomes, 2020, 13(10): e006515.
|
[23] |
Food and Drug Administration. FDA 2015 prescribing information, pradaxa[DB/OL]. 2015:
URL
|
[24] |
Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment [J]. Eur Heart J, 2011, 32(19): 2387-2394.
|
[25] |
Food and Drug Administration. Label information for Xarelto[DB/OL]. 2017:
URL
|
[26] |
Dias C, Moore KT, Murphy J, et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis [J]. Am J Nephrol, 2016, 43(4): 229-236.
|
[27] |
Weir MR, Ashton V, Moore KT, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease [J]. Am Heart J, 2020, 223: 3-11.
|
[28] |
De Vriese AS, Caluwé R, Van Der Meersch H, et al. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial [J]. J Am Soc Nephrol, 2021, 32(6): 1474-1483.
|
[29] |
Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial [J]. Eur Heart J, 2012, 33(22): 2821-2830.
|
[30] |
Deal EN, Pope H, Ross W. Apixaban use among patients with severe renal impairment [J]. Ann Pharmacother, 2014, 48(12): 1667.
|
[31] |
Mavrakanas TA, Samer CF, Nessim SJ, et al. Apixaban pharmacokinetics at steady state in hemodialysis patients [J]. J Am Soc Nephrol, 2017, 28(7): 2241-2248.
|
[32] |
Pokorney SD, Chertow GM, Al-Khalidi HR, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial [J]. Circulation, 2022, 146(23): 1735-1745.
|
[33] |
Reinecke H, Engelbertz C, Bauersachs R, et al. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study [J]. Circulation, 2023, 147(4): 296-309.
|
[34] |
Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial [J]. Circulation, 2016, 134(1): 24-36.
|
[35] |
Food and Drug Administration. Label information for Savaysa [DB/OL]. 2017:
URL
|
[36] |
Food and Drug Administration. Label information for Bevyxxa [DB/OL]. 2017:
URL
|
[37] |
Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa) [J]. Eur Heart J, 2013, 34(20): 1498-1505.
|
[38] |
Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients [J]. N Engl J Med, 2016, 375(6): 534-544.
|
[39] |
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society [J]. J Am Coll Cardiol, 2014, 64(21): e1-e76.
|
[40] |
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS [J]. Eur Heart J, 2016, 37(38): 2893-2962.
|
[41] |
Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation [J]. Chest, 2010, 137(2): 263-272.
|
[42] |
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons [J]. Circulation, 2019, 140(2): e125-e151.
|
[43] |
Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary [J]. Europace, 2018, 20(8): 1231-1242.
|
[44] |
Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) [J]. Kidney Int, 2011, 80(6): 572-586.
|
[45] |
Kuno T, Takagi H, AndoT, et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis [J]. J Am Coll Cardiol, 2020, 75(3): 273-285.
|
[46] |
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey [J]. Chest, 2010, 138(5): 1093-1100.
|